tbuckley/cabot-search huggingface dataset:
Mechanisms of cancer metastasis
Authors: Maria Castaneda, Petra den Hollander, Nick A. Kuburich, Jeffrey M. Rosen, Sendurai A. Mani
Journal: Seminars in Cancer Biology (2022)

Metastatic cancer is almost always terminal, and more than 90% of cancer deaths result from metastatic disease. Combating cancer metastasis and post-therapeutic recurrence successfully requires understanding each step of metastatic progression. This review describes the current state of knowledge of the etiology and mechanism of cancer progression from primary tumor growth to the formation of new tumors in other parts of the body. Open questions, avenues for future research, and therapeutic approaches with the potential to prevent or inhibit metastasis through personalization to each patient's mutation and/or immune profile are also highlighted.
Endoscopic ligation technique with O-ring closure: improved or complicated?
Authors: Zhi-Han Wu, Mo Chen, Kai Deng
Journal: Endoscopy (2022)

See also: Efficacy of endoscopic ligation with O-ring closure for prevention of bleeding after gastric endoscopic submucosal dissection under antithrombotic therapy: a prospective observational studyEndoscopy 2022; 54(11): 1078-1084DOI: 10.1055/a-1782-3448 See also: Reply to Wu et al.Endoscopy 2022; 54(11): 1126-1126DOI: 10.1055/a-1904-8093
Integrating Internet multisource big data to predict the occurrence and development of COVID-19 cryptic transmission
Authors: Chengcheng Gao, Rui Zhang, Xicheng Chen, Tianhua Yao, Qiuyue Song, Wei Ye, PengPeng Li, Zhenyan Wang, Dong Yi, Yazhou Wu
Journal: npj Digital Medicine (2022)

With the recent prevalence of COVID-19, cryptic transmission is worthy of attention and research. Early perception of the occurrence and development risk of cryptic transmission is an important part of controlling the spread of COVID-19. Previous relevant studies have limited data sources, and no effective analysis has been carried out on the occurrence and development of cryptic transmission. Hence, we collect Internet multisource big data (including retrieval, migration, and media data) and propose comprehensive and relative application strategies to eliminate the impact of national and media data. We use statistical classification and regression to construct an early warning model for occurrence and development. Under the guidance of the improved coronavirus herd immunity optimizer (ICHIO), we construct a "sampling-feature-hyperparameter-weight" synchronous optimization strategy. In occurrence warning, we propose an undersampling synchronous evolutionary ensemble (USEE); in development warning, we propose a bootstrap-sampling synchronous evolutionary ensemble (BSEE). Regarding the internal training data (Heilongjiang Province), the ROC-AUC of USEE3 incorporating multisource data is 0.9553, the PR-AUC is 0.8327, and the R2 of BSEE2 fused by the "nonlinear + linear" method is 0.8698. Regarding the external validation data (Shaanxi Province), the ROC-AUC and PR-AUC values of USEE3 were 0.9680 and 0.9548, respectively, and the R2 of BSEE2 was 0.8255. Our method has good accuracy and generalization and can be flexibly used in the prediction of cryptic transmission in various regions. We propose strategy research that integrates multiple early warning tasks based on multisource Internet big data and combines multiple ensemble models. It is an extension of the research in the field of traditional infectious disease monitoring and has important practical significance and innovative theoretical value.
Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
Authors: Aram Bidikian, Hagop Kantarjian, Elias Jabbour, Nicholas J. Short, Keyur Patel, Farhad Ravandi, Koji Sasaki, Ghayas C. Issa
Journal: Blood Cancer Journal (2022)

Abstract While the clinical impact of mutations in the ABL1 gene on response to therapy in chronic phase chronic myeloid leukemia (CP-CML) is well established, less is known about how other mutations affect prognosis. In a retrospective analysis, we identified 115 patients with CML (71 chronic, 15 accelerated and 29 blast phase) where targeted next-generation sequencing of genes recurrently mutated in myeloid leukemias was performed. ASXL1 was the most frequently mutated gene in the chronic (14%) and accelerated phase (40%) CML patients, whereas RUNX1 (20%) was the most common mutation in blast phase. Compared with wild-type ASXL1 , CP-CML with mutant ASXL1 was associated with worse event-free survival (EFS) (median of 32.8 vs 88.3 months; P = 0.002) and failure-free survival (median of 13.8 vs 57.8 months; P = 0.04). In a multivariate analysis, ASXL1 mutation was the only independent risk factor associated with worse EFS in chronic phase CML with a hazard ratio of 4.25 (95% CI 1.59–11.35, P = 0.004). In conclusion, mutations in ASXL1 are associated with worse outcomes when detected in chronic phase CML.
MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells
Authors: Lea Duwe, Patricia Munoz-Garrido, Monika Lewinska, Juan Lafuente-Barquero, Letizia Satriano, Dan Høgdall, Andrzej Taranta, Boye S. Nielsen, Awaisa Ghazal, Matthias S. Matter, Jesus M. Banales, Blanca I. Aldana, Yu-Tang Gao, Jens U. Marquardt, Lewis R. Roberts, Rui C. Oliveira, Jill Koshiol, Colm J. O'Rourke, Jesper B. Andersen
Journal: Journal of Hepatology (2022)

Cholangiocarcinoma (CCA) is a heterogeneous and lethal malignancy, the molecular origins of which remain poorly understood. MicroRNAs (miRs) target diverse signalling pathways, functioning as potent epigenetic regulators of transcriptional output. We aimed to characterise miRNome dysregulation in CCA, including its impact on transcriptome homeostasis and cell behaviour.Small RNA sequencing was performed on 119 resected CCAs, 63 surrounding liver tissues, and 22 normal livers. High-throughput miR mimic screens were performed in three primary human cholangiocyte cultures. Integration of patient transcriptomes and miRseq together with miR screening data identified an oncogenic miR for characterization. MiR-mRNA interactions were investigated by a luciferase assay. MiR-CRISPR knockout cells were generated and phenotypically characterized in vitro (proliferation, migration, colony, mitochondrial function, glycolysis) and in vivo using subcutaneous xenografts.In total, 13% (140/1,049) of detected miRs were differentially expressed between CCA and surrounding liver tissues, including 135 that were upregulated in tumours. CCA tissues were characterised by higher miRNome heterogeneity and miR biogenesis pathway expression. Unsupervised hierarchical clustering of tumour miRNomes identified three subgroups, including distal CCA-enriched and IDH1 mutant-enriched subgroups. High-throughput screening of miR mimics uncovered 71 miRs that consistently increased proliferation of three primary cholangiocyte models and were upregulated in CCA tissues regardless of anatomical location, among which only miR-27a-3p had consistently increased expression and activity in several cohorts. FoxO signalling was predominantly downregulated by miR-27a-3p in CCA, partially through targeting of FOXO1. MiR-27a knockout increased FOXO1 levels in vitro and in vivo, impeding tumour behaviour and growth.The miRNomes of CCA tissues are highly remodelled, impacting transcriptome homeostasis in part through regulation of transcription factors like FOXO1. MiR-27a-3p arises as an oncogenic vulnerability in CCA.Cholangiocarcinogenesis entails extensive cellular reprogramming driven by genetic and non-genetic alterations, but the functional roles of these non-genetic events remain poorly understood. By unveiling global miRNA upregulation in patient tumours and their functional ability to increase proliferation of cholangiocytes, these small non-coding RNAs are implicated as critical non-genetic alterations promoting biliary tumour initiation. These findings identify possible mechanisms for transcriptome rewiring during transformation, with potential implications for patient stratification.
Chronic rhinosinusitis patients display an aberrant immune cell localization with enhanced S aureus biofilm metabolic activity and biomass
Authors: Gohar Shaghayegh, Clare Cooksley, George Spyro Bouras, Beula Subashini Panchatcharam, Rejhan Idrizi, Metta Jana, Sarah Ellis, Alkis James Psaltis, Peter-John Wormald, Sarah Vreugde
Journal: Journal of Allergy and Clinical Immunology (2022)
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes
Authors: George L. Bakris, Luis M. Ruilope, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Linda Fried, Prabir Roy-Chaudhury, Pantelis Sarafidis, Christiane Ahlers, Meike Brinker, Amer Joseph, Robert Lawatscheck, Rajiv Agarwal
Journal: Kidney International (2022)

In FIDELITY, a prespecified pooled analysis of the FIDELIO-DKD and FIGARO-DKD studies, finerenone was found to improve cardiorenal outcomes in patients with type 2 diabetes, a urine albumin-to-creatinine ratio of 30-5000 mg/g, an estimated glomerular filtration rate (eGFR) of 25 ml/min per 1.73 m2 or more and also receiving optimized renin-angiotensin system blockade treatment. This present analysis focused on the efficacy and safety of finerenone on kidney outcomes. Among 13,026 patients with a median follow-up of three years, finerenone significantly reduced the hazard of a kidney composite outcome (time to kidney failure, sustained 57% or more decrease in eGFR from baseline, or kidney death) by 23% versus placebo (hazard ratio, 0.77; 95% confidence interval, 0.67-0.88), with a three-year absolute between-group difference of 1.7% (95% confidence interval, 0.7-2.6). Hazard ratios were directionally consistent for a prespecified baseline eGFR and urine albumin-to-creatinine ratio categories (Pinteraction = 0.62 and Pinteraction = 0.67, respectively), although there was a high degree of uncertainty in the 30-300 mg/g subgroup. Finerenone significantly reduced the hazard of end-stage kidney disease (ESKD) by 20% versus placebo (0.80; 0.64-0.99). Adverse events were similar between treatment arms, although hyperkalemia leading to treatment discontinuation occurred significantly more frequently with finerenone versus placebo (2.4% vs 0.8% and 0.6% vs 0.3% in patients with eGFR less than 60 vs. greater than or equal to 60 ml/min per 1.73 m2, respectively). Thus, finerenone improved kidney outcomes, reduced the hazard of ESKD, and is well tolerated in patients with chronic kidney disease and type 2 diabetes.
Uncovering risk factors for kidney injury in children with a solitary functioning kidney
Authors: Sander Groen in ‘t Woud, Nel Roeleveld, Rik Westland, Kirsten Y. Renkema, Martijn G. Steffens, Valentina Gracchi, Marc R. Lilien, Joanna A.E. van Wijk, Wout F.J. Feitz, Michiel F. Schreuder, Loes F.M. van der Zanden, M.C.G. Beeren, H.E. Blokland-Loggers, M. Breukels, L.M. van den Broek, R. del Canho, D. Creemers, C.M.L. van Dael, H. van der Deure, A. Dings-Lammertink, C. Dorrepaal, E. Dorresteijn, W.F.J. Feitz, V. Gracchi, S. Groen in ‘t Woud, E. Harnisch, M.J. Jacobs, P.E. Jira, M.G. Keijzer-Veen, F.J. Kloosterman, E. Knots, A.Y. Konijnenberg, M. Koppejan-Stapel, E.C. van der Kuur, M.J. van Ledden-Klok, R.W.J. Leunissen, M.R. Lilien, C. Meine Jansen, R. de Moor, I.J.M. Nijhuis, L.J.W.M. Pierik, A. Pijning, S.M.H.B. de Pont, K.Y. Renkema, R. Rijlaarsdam, N. Roeleveld, R.W.G. van Rooij, M.F. Schreuder, B. Semmekrot, M.G. Steffens, A.L. Tanja, R. Westland, J.A.E. van Wijk, E. Wijnands - van den Berg, L.F.M. van der Zanden, B. Zegers
Journal: Kidney International (2022)

Children with a solitary functioning kidney (SFK) have an increased risk of kidney injury. The exact risk of and risk factors for kidney injury remain unknown, which impedes personalized care. Here, we recruited a nationwide multicenter cohort of 944 patients with SFK to get more insight into this by consenting patients born in 1993-2020 and diagnosed with congenital or acquired SFK before adulthood. The median follow-up was 12.8 years and four indications of kidney injury were studied: urine protein-creatinine ratios, blood pressure, estimated glomerular filtration rate and use of anti-hypertensive/proteinuric medication. For each indicator except medication use, separate cut-off values for any injury and severe injury were used. Survival analyses indicated that at 18 years of age, any or severe kidney injury were present in 75% and 39% of patients with congenital SFK, respectively. Risk factors for kidney injury included kidney agenesis as cause of the SFK, anomalies in the SFK, and high body mass index at last follow-up. Kidney agenesis and being overweight were specifically associated with proteinuria and high blood pressure, whereas anomalies in the SFK were associated with reduced estimated glomerular filtration rates. The high prevalence of kidney injury in patients with SFK emphasizes the need for long-term follow-up, in which lifestyle is an important topic to address. More research into the etiological role of risk factors will help to translate our findings into individualized care strategies. Thus, our study shows that a significant proportion of children with SFK will develop kidney injury over time.
Association between cholinesterase inhibitors and kidney function decline in patients with Alzheimer’s dementia
Authors: Hong Xu, Sara Garcia-Ptacek, Annette Bruchfeld, Edouard L. Fu, Taher Darreh Shori, Bengt Lindholm, Maria Eriksdotter, Juan Jesus Carrero
Journal: Kidney International (2022)

Preclinical evidence shows that activation of the cholinergic anti-inflammatory pathway (CAP) may have direct and indirect beneficial effects on the kidney. Cholinesterase inhibitors (ChEIs) are specific Alzheimer's dementia (AD) therapies that block the action of cholinesterases and activate CAP. Here, we explored a plausible effect of ChEIs on slowing kidney function decline by comparing the risk of CKD progression among patients with newly diagnosed AD that initiated ChEI or not within 90 days. Using complete information of routine serum creatinine tests, we evaluated changes in estimated glomerular filtration rate (eGFR) and defined the outcome of chronic kidney disease (CKD) progression as the composite of an eGFR decline of over 30%, initiation of dialysis/transplant or death attributed to CKD. A secondary outcome was death. Inverse probability of treatment-weighted Cox regression was used to estimate hazard ratios. Among 11, 898 patients, 6,803 started on ChEIs and 5,095 did not. Mean age was 80 years (64% women) and the mean eGFR was 68 ml/min/1.73m2. During a median 3.0 years of follow-up, and compared to non-use, ChEI use was associated with 18% lower risk of CKD progression (1,231 events, adjusted hazard ratio 0.82; 95% confidence interval 0.71-0.96) and a 21% lower risk of death (0.79; 0.72-0.86). Results were consistent across subgroups, ChEI subclasses and after accounting for competing risks. Thus, in patients with AD undergoing routine care, use of ChEI (vs no-use) was associated with lower risk of CKD progression.
Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
Authors: Juanjuan Feng, Zhengke Lian, Xinting Xia, Yue Lu, Kewen Hu, Yunpeng Zhang, Yanan Liu, Longmiao Hu, Kun Yuan, Zhenliang Sun, Xiufeng Pang
Journal: Acta Pharmaceutica Sinica B (2022)

MEK is a canonical effector of mutant KRAS; however, MEK inhibitors fail to yield satisfactory clinical outcomes in KRAS-mutant cancers. Here, we identified mitochondrial oxidative phosphorylation (OXPHOS) induction as a profound metabolic alteration to confer KRAS-mutant non-small cell lung cancer (NSCLC) resistance to the clinical MEK inhibitor trametinib. Metabolic flux analysis demonstrated that pyruvate metabolism and fatty acid oxidation were markedly enhanced and coordinately powered the OXPHOS system in resistant cells after trametinib treatment, satisfying their energy demand and protecting them from apoptosis. As molecular events in this process, the pyruvate dehydrogenase complex (PDHc) and carnitine palmitoyl transferase IA (CPTIA), two rate-limiting enzymes that control the metabolic flux of pyruvate and palmitic acid to mitochondrial respiration were activated through phosphorylation and transcriptional regulation. Importantly, the co-administration of trametinib and IACS-010759, a clinical mitochondrial complex I inhibitor that blocks OXPHOS, significantly impeded tumor growth and prolonged mouse survival. Overall, our findings reveal that MEK inhibitor therapy creates a metabolic vulnerability in the mitochondria and further develop an effective combinatorial strategy to circumvent MEK inhibitors resistance in KRAS-driven NSCLC.
Perturbated glucose metabolism augments epithelial cell proinflammatory function in chronic rhinosinusitis
Authors: Cai-Ling Chen, Jin Ma, Ruo-Yu Lu, Yu-Ting Wang, Jie-Fang Zhao, Yi-Fan Kang, Jun-Jian Hu, Nan Wang, Jia Song, Jixin Zhong, Chen Chen, Heng Wang, Zheng Liu
Journal: Journal of Allergy and Clinical Immunology (2022)
An off-the-shelf multi-well scaffold-supported platform for tumour organoid-based tissues
Authors: Nancy T. Li, Nila C. Wu, Ruonan Cao, Jose L. Cadavid, Simon Latour, Xiaoya Lu, Yutong Zhu, Mirjana Mijalkovic, Reza Roozitalab, Natalie Landon-Brace, Faiyaz Notta, Alison P. McGuigan
Journal: Biomaterials (2022)
Antimicrobial susceptibility testing in clinical Mycobacterium tuberculosis isolates
Authors: Jiachen Li, Siyuan Feng, Yuhui Chen, Meiling Yu, Wenjing Wei, Guo-Bao Tian
Journal: The Lancet Microbe (2022)

Whole-genome sequencing (WGS) for prediction of drug resistance in Mycobacterium tuberculosis clinical isolates might contribute to the timely diagnosis and correct treatment of all tuberculosis cases. In 2021, the first catalogue of resistance-associated mutations in clinical M tuberculosis complex isolates was published by WHO,1 which provided a global standard for resistance interpretation. We read with interest the Article by Finci and colleagues2 reporting a good correlation between resistance genotype with phenotypic antimicrobial susceptibility testing (AST) using a large, longitudinal survey of M tuberculosis isolates from five countries.
Efficacy and safety of moxidectin and albendazole compared with ivermectin and albendazole coadministration in adolescents infected with Trichuris trichiura in Tanzania: an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
Authors: Sophie Welsche, Emmanuel C Mrimi, Jan Hattendorf, Eveline Hürlimann, Said M Ali, Jennifer Keiser
Journal: The Lancet Infectious Diseases (2022)
Nucleic acid nanoassembly-enhanced RNA therapeutics and diagnosis
Authors: Mengnan Zhao, Rujing Wang, Kunmeng Yang, Yuhong Jiang, Yachen Peng, Yuke Li, Zhen Zhang, Jianxun Ding, Sanjun Shi
Journal: Acta Pharmaceutica Sinica B (2022)

RNAs are involved in the crucial processes of disease progression and have emerged as powerful therapeutic targets and diagnostic biomarkers. However, efficient delivery of therapeutic RNA to the targeted location and precise detection of RNA markers remains challenging. Recently, more and more attention has been paid to applying nucleic acid nanoassemblies in diagnosing and treating. Due to the flexibility and deformability of nucleic acids, the nanoassemblies could be fabricated with different shapes and structures. With hybridization, nucleic acid nanoassemblies, including DNA and RNA nanostructures, can be applied to enhance RNA therapeutics and diagnosis. This review briefly introduces the construction and properties of different nucleic acid nanoassemblies and their applications for RNA therapy and diagnosis and makes further prospects for their development.
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial
Authors: Ingrid M Bistervels, Andrea Buchmüller, Hanke M G Wiegers, Fionnuala Ní Áinle, Bernard Tardy, Jennifer Donnelly, Peter Verhamme, Anne F Jacobsen, Anette T Hansen, Marc A Rodger, Maria T DeSancho, Roman G Shmakov, Nick van Es, Martin H Prins, Céline Chauleur, Saskia Middeldorp, Eline S van den Akker, Mireille N Bekker, Thomas van Bemmel, Laurent Bertoletti, Julie Blanc, Suzanne M Bleker, Aude Bourtembourg-Matras, Florence Bretelle, Bridgette Byrne, Francis Couturaud, Pierre Delorme, Elise S Eerenberg, Maureen TM Franssen, Jens Fuglsang, Wessel Ganzevoort, François Goffinet, Jiska M de Haan-Jebbink, Wieteke Heidema, Monique A Hertzberg, Marcel MC Hovens, Menno V Huisman, Leonie de Jong-Speksnijder, Pieter-Willem Kamphuisen, Denis J O'Keeffe, Karine Lacut, Josje Langenveld, M Simone Lunshof, Caroline P Martens, Adel Merah, Emmanuelle Le Moigne, Dimitri NM Papatsonis, Gilles Pernod, Franck Perrotin, Edith Peynaud-Debayle, Fabrice Pierre, Geneviève Plu Bureau, Tiphaine Raia-Barjat, Robbert JP Rijnders, Roger Rosario, Marc Ruivard, Jeannot Schmidt, Marieke Sueters, Thomas Vanassche, Marie-Noëlle Varlet, Alexandre J Vivanti, Matthieu Y van der Vlist, Lucet F van der Voet, Karlijn C Vollebregt, Johanna IP de Vries, Sabina de Weerd, Peter E Westerweel, Lia DE Wijnberger, Marije ten Wolde, Paula F Ypma, Catherine Zuily-Lamy, Joost J Zwart, Alexandra Benachi, Gaël Beucher, Holy Bezanahary, Karin de Boer, Marjon A. de Boer, Frantz Bousquet, Henk A. Bremer, Luc Bressollette, Aurélie Brossard, Cécile Chau, Brian Cleary, Fabienne Comte, Thomas Corsini, Anne Coustel, Barbara Debaveye, Raoul Desbrière, Cécile Duvillard, Astrid Eckman, Jeroen Eikenboom, Antoine Elias, Laura M. Faber, Emile Ferrari, Denis Gallot, Emilie Gauchotte, Ingrid Gaugler, Abby E. Geerlings, Audrey O'Gorman, Vincent Grobost, Pieter-Kees de Groot, David P. van der Ham, Brenda Hermsen, Kim Kamphorst, Alan Karovitch, Gunilla Kleiverda, Aiste Kloster, Annemarieke Koops, Inneke Krabbendam, Marieke J.H.A. Kruip, Saskia Kuipers, Judith van Laar, Damien Laneelle, Suzanne Lima, Peter MacMahon, Laurent Mandelbrot, Claudia A. van Meir, Caroline Menez, Leonard P. Morssink, Nathalie Moulin, Eve Mousty, Matthieu Muller, Lucy Murphy, Kathelijne Peerlinck, Alma O'Reilly, Maartje de Reus, Magali Hilmi Le Roux, Kevin Ryan, Bettina Samren, Daniela Schippers, Nico Schuitemaker, Chloé Schweizer, Hanneke van der Straaten, Cécile Tromeur, Kristine Vanheule, Tamara Verhagen, Jantien Visser, Michael Watts, Wim J. van Wijngaarden, Mallory Woiski, Maartje Zelis
Journal: The Lancet (2022)
Innovations, adaptations, and accelerations in the delivery of HIV services during COVID-19
Authors: Eamonn Murphy, Meg Doherty, Wafaa El Sadr, Irum Zaidi, Adeeba Kamarazulman, Siobhan Crowley, Florence Riako Anam, Chinmay Modi, Erika Castellanos, Alex Garner, Neil McCulloch, Aditia Taslim, Paulie “Amanita” Calderon Cifuentes, Peter D Ghys, Peter Godfrey-Faussett, Luisa Frescura, Kevin M DeCock
Journal: The Lancet HIV (2022)
Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial
Authors: Pengfei Yang, Lili Song, Yongwei Zhang, Xiaoxi Zhang, Xiaoying Chen, Yunke Li, Lingli Sun, Yingfeng Wan, Laurent Billot, Qiang Li, Xinwen Ren, Hongjian Shen, Lei Zhang, Zifu Li, Pengfei Xing, Yongxin Zhang, Ping Zhang, Weilong Hua, Fang Shen, Yihan Zhou, Bing Tian, Wenhuo Chen, Hongxing Han, Liyong Zhang, Chenghua Xu, Tong Li, Ya Peng, Xincan Yue, Shengli Chen, Changming Wen, Shu Wan, Congguo Yin, Ming Wei, Hansheng Shu, Guangxian Nan, Sheng Liu, Wenhua Liu, Yiling Cai, Yi Sui, Maohua Chen, Yu Zhou, Qiao Zuo, Dongwei Dai, Rui Zhao, Qiang Li, Qinghai Huang, Yi Xu, Benqiang Deng, Tao Wu, Jianping Lu, Xia Wang, Mark W Parsons, Ken Butcher, Bruce Campbell, Thompson G Robinson, Mayank Goyal, Diederik Dippel, Yvo Roos, Charles Majoie, Longde Wang, Yongjun Wang, Jianmin Liu, Craig S Anderson
Journal: The Lancet (2022)